SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Cellect Biotechnology Ltd.
(Exact Name of Registrant as Specified in its Charter)
|State of Israel||Not Applicable|
|(State or Other Jurisdiction of||(IRS Employer|
|Incorporation or Organization)||Identification No.)|
23 Hata’as Street
Kfar Saba, Israel
|(Address of principal executive offices)||(Zip Code)|
Securities to be registered pursuant to Section 12(b) of the Act:
|Title of each class to be registered||Name of each exchange on which each class is to be registered|
|American Depositary Shares, each representing twenty (20) Ordinary Shares, no par value per share||The Nasdaq Stock Market LLC|
|Warrants to purchase American Depositary Shares||The Nasdaq Stock Market LLC|
|Ordinary Shares, no par value per share*||N/A|
* Not for trading, but only in connection with the registration of the American Depositary Shares pursuant to requirements of the Securities and Exchange Commission.
If this Form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), please check the following box. x
If this Form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), please check the following box. ¨
If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ¨
Securities Act registration statement or Regulation A Offering Statement file number to which this form relates: 333-212432
Securities to be registered pursuant to Section 12(g) of the Act: None.
Item 1. Description of Registrant's Securities to be Registered.
The description of American Depositary Shares and warrants to purchase American Depositary Shares of Cellect Biotechnology Ltd. (the “Registrant”), as included under the caption “Description of Securities” in the prospectus forming a part of the Registration Statement on Form F-1, as amended (Registration No. 333-212432) (the “Registration Statement”), filed under the Securities Act of 1933, as amended (the “Securities Act”), is incorporated by reference herein. In addition, any description of such securities contained in a form of prospectus relating to the Registration Statement subsequently filed by the Company pursuant to Rule 424(b) under the Securities Act shall be deemed to be incorporated by reference herein.
Item 2. Exhibits.
Under the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
|Cellect Biotechnology Ltd.|
|Date: July 27, 2016||By:||/s/ Dr. Shai Yarkoni|
|Name: Dr. Shai Yarkoni|
|Title: Chief Executive Officer|